Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.5%

2 terminated out of 44 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

36%

16 trials in Phase 3/4

Results Transparency

36%

8 of 22 completed with results

Key Signals

8 with results92% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (5)
Early P 1 (2)
P 1 (9)
P 2 (8)
P 3 (5)
P 4 (11)

Trial Status

Completed22
Unknown9
Recruiting7
Terminated2
Active Not Recruiting2
Suspended1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (44)

Showing 20 of 20 trials
NCT06606587Not ApplicableCompletedPrimary

Effectiveness of the Comfort-In Needle Free Injection System During Palatal Infiltrative Anesthesia

NCT06462196Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

NCT05615948Phase 4Completed

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT06511908Phase 2Recruiting

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT07122193Phase 3Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07210463Phase 3Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

NCT06535568Not ApplicableRecruiting

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

NCT04289142Phase 4Recruiting

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

NCT07167550Phase 3Recruiting

The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke

NCT05288166Phase 3Active Not Recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT02242968Completed

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT05284097Phase 2Completed

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

NCT03646292Phase 4Completed

Antidiabetic Drugs for Steatotic Liver Disease

NCT03964350Early Phase 1Completed

Behavior Brain Responses

NCT04310592Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

NCT04045301Phase 2Active Not Recruiting

Omalizumab to Accelerate a Symptom-driven Multi-food OIT

NCT05794503Phase 4Completed

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05657860Phase 4Completed

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05321602Phase 1Completed

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

NCT05132829Phase 4Unknown

Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial

Scroll to load more

Research Network

Activity Timeline